Institutional cost savings through dose banding strategy of Pembrolizumab in oncology patients: a real-world data analysis. Univ. Sci. [Internet]. 2025 Nov. 4 [cited 2025 Nov. 10];:S19. Available from: https://revistas.javeriana.edu.co/index.php/scientarium/article/view/41540